Our site uses cookies to improve the contents of the site and customize it according to individual use. Please confirm that you agree to our use of cookies by clicking Yes.

If you continue without explicit consent,
we will assume that you agree to our cookie policy.

MEDISOA comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

厚生労働省

2026年4月28日(火)~2026年5月6日(水)は、休業とさせていただきます。
この期間中にお受けしたお問い合せ・ご相談の申込みについては、休業明けに対応させていただきます。
何卒ご了承のほどお願いいたします。

What is MEDISO

MEDISO provides support for business ventures, academia,
and individuals intending to put into practical use medicines,
medical devices, and regenerative medicinal products.
Click here for further details.

About the Medical Innovation Support Office

The medical innovation support office matches medical venture companies and academic institutions facing challenges in the practical application of medical products and devices for specialists* who provide detailed consultation and support for solving problems at each stage from research and development to practical use, as well as insurance coverage at clinical sites, while looking ahead to the overall comprehensive advances and dissemination into the global market.
* Specialists in each field provide support for the response to laws and regulations, marketing, business planning, fund rasing, management strategy, intellectual property management, and international development, etc.

This website is operated by Mitsubishi Research Institute, Inc., as a trustee under instructions from the Economic Affairs Division, Health Policy Bureau, and Ministry of Health, Labour and Welfare as a part of the total support for the medical ventures program sponsored by the Ministry of Health, Labour and Welfare.

Support targets

Ventures, academic institutions, and individuals aiming to put into practical use the medicines, medical devices, regenerative medicinal products, and novel drug-discovery technologies or medical materials subject to the Pharmaceuticals and Medical Devices Law.

Details of support

MEDISO provides support for the practical application of medicines, medical devices, regenerative medicinal products, and other products subject to the Pharmaceuticals and Medical Devices Law.
That support includes business planning, financing, advice on laws and regulations, and other assistance as required.

Click here for inquiries

In case the link does not work, please contact us at the email address below
mediso@ml.mri.co.jp

Specialists Introduction

We will introduce registered specialists
(updated as necessary).

Aiko Kato Sullenberger

RykoTECH President

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Marketing
  • Business planning
  • Funding
  • Business operation systems

Aiko Kato Sullenberger, CEO of RykoTECH, a significant contributor within the Boston startupecosystem for several years, brings a wealth of experience in various roles, spanning investor,startup, and accelerator. She provides specialized advisory services comprehensive strategicconsultation and facilitation of market entry into the US across diverse sectors, including drugdiscovery, medical devices, digital health, digital therapeutics and biotech. Aiko can help   • Fundraising • Strategic Partnership Development • Create Deal Flow (Connecting with Potential Investors) • Identifying Partners and Advisors • Assistance in Facilitating Clinical Trials • Corporate Strategy: Investment Thesis, Portfolio Analysis • Market / Trend Research & Analysis • Go-to-Market Strategy • Academic Business Liaison: Interdisciplinary Project Lead • Cross-Functional Team Building

Teppei Konishi

Biomy Inc. CEO

Main specialty areas

  • medical devices

Specialized support fields

  • Regulatory compliance
  • Business planning
  • Funding
  • Business operation systems
  • Etc

He completed his graduate studies at the Graduate School of Engineering Science, Osaka University. At NTT DOCOMO, he specialized in big data analysis and AI-driven video analysis research, contributing to new business development. After leaving NTT DOCOMO, he served as CTO at an IT venture before founding Biomy Co., Ltd. There, he led the development of a personalized medical platform utilizing AI technology, collaborating with domestic and international pharmaceutical companies and research institutions. He also secured a Class II medical device manufacturing and sales license.

Motohiro Kobayashi

University of Yamanashi Hospital, Clinical Trial Management Office, Associate Professor

Main specialty areas

  • medicines
  • regenerative medicine products

Specialized support fields

  • Regulatory compliance
  • Business planning
  • Business operation systems

With over 30 years of practical experience in pharmaceutical companies, ranging from basic research to clinical development, licensing activities, and regulatory audits. Subsequently, I served as a technical expert in the Innovation Commercialization Support & Strategic Consultation Division of the Pharmaceuticals and Medical Devices Agency (PMDA), dealing with regulatory consultation services for academia and venture companies (especially for regenerative medicine products and pharmaceuticals). Currently, I am working in the clinical research support department of a university, supporting physician-led clinical trials and clinical research. I have experienced numerous pre-meetings and face-to-face advice with PMDA. I also have experience in application support for public research and development projects (such as Seeds C, etc.) by the Japan Agency for Medical Research and Development (AMED). In particular, I can provide detailed support for the development of regenerative medicine products (including quality and non-clinical).

Masanori Sato

ReachMed Partners LLC President

Main specialty areas

  • medicines
  • regenerative medicine products

Specialized support fields

  • Marketing
  • Business planning
  • Funding
  • Business operation systems
  • Etc

Masanori has extensive experience in pharmaceutical R&D, alliance management, and business development. Their career evolved into leadership roles in global product launches, strategic licensing, and early-stage clinical development, particularly in antiviral therapeutics at a R&D focused pharmaceutical division of a leading Japanese conglomerate. Later, as head of the business development department, they managed global licensing agreements and partnerships with major pharmaceutical companies in the U.S. and Europe for multiple in-house pipeline assets. Since 2016, they have held leadership roles in alliance management and business development at leading U.S. biotech and European pharmaceutical companies, focusing on partnerships with Japanese firms, contract negotiations, and search & evaluation of external technologies/assets across Japan and the Asia-Pacific region. From 2021, they joined a top Japanese pharmaceutical company, where they led open innovation initiatives, incubation of internal and external seed assets, and support for venture investments. During this time, they also served as a board member for a portfolio biotech companies. In March 2025, they founded their own company, leveraging their broad expertise and network to support Japanese biotech startups and assist international startups into Japan. They hold national license for Small and Medium Enterprise Management Consultant, among others.

Masashi Matsunaga

Biospire Japan Ltd. / Biospire UK Ltd.
CEO

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Marketing
  • Business planning
  • Funding
  • Business operation systems

As an experienced global business development strategist, Dr Masashi Matsunaga provides business soft-landing, clinical and regulatory support to the UK and European market. He also enables to support IP management, marketing and pitch-deck brush-up in the MEDISO support package. He is based at Harwell Science & Innovation Campus, a core UK innovation hub located near Oxford.

About details of specialists

Introduction of measures implemented by public institutions

We will describe the measures from public institutions for pharmaceutical companies,
medical device companies, companies manufacturing regenerative medicinal products, and venture companies.

See more about measures implemented by public institutions